22nd week of 2012 patent applcation highlights part 33 |
Patent application number | Title | Published |
20120134918 | GUM ARABIC COATED 198GOLD RADIOACTIVE NANOPARTICLES FOR CANCER THERAPY - The invention provides a cancer therapeutic and imaging agent comprising a solution containing Gum Arabic coated | 2012-05-31 |
20120134919 | Ion substituted calcium phosphate particles - A method for formation of spherical particles of ion substituted calcium phosphate. The method is based on precipitation of particles from a buffered solution under static, stirring or hydrothermal conditions. Also, the use of the formed materials and the particles in itself. | 2012-05-31 |
20120134920 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 2012-05-31 |
20120134921 | SOLID COMPOSITIONS COMPRISING 5-AMINOLEVULINIC ACID - This invention relates to solid compositions and solid pharmaceutical products for use in methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions in the lower part of the gastrointestinal system. The solid pharmaceutical compositions and pharmaceutical products comprise an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative of 5-ALA or pharmaceutically acceptable salts thereof. The invention relates further to methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions of the lower gastrointestinal tract, wherein the solid pharmaceutical compositions and pharmaceutical products are used. | 2012-05-31 |
20120134922 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE - Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A—X—B—C)n—M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier. | 2012-05-31 |
20120134923 | RADIOIODINATION METHOD - The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using. | 2012-05-31 |
20120134924 | Micro-Vesicles Providing Contrast To Target Tissue Electrical Property Gradients - Micro-vesicles that become acoustically sensitive in the presence of a Radio Frequency (RF) Electromagnetic (EM) field are presented. The micro-vesicles can comprise a main body having one or more affinity ligands configured to preferentially bind to a target tissue. Once bound, the micro-vesicles and the target tissue can be bathed in an RF EM field, which induces the target tissue or micro-vesicles to generate an acoustic signal. The micro-vesicles can also become receptive to acoustic energy. An acoustic therapeutic signal can be directed toward the target tissue and micro-vesicles, which causes therapeutic excitation of the micro-vesicles. The therapeutic excitation can include heating the target tissue, releasing a drug formulation, or other excitation. The disclosed techniques can be used with a high degree of precision to activate micro-vesicles local to the target tissue. | 2012-05-31 |
20120134925 | Application and Uses of PRG4 and Therapeutic Modulation Thereof - The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication. | 2012-05-31 |
20120134926 | CHARGE-DYNAMIC POLYMERS AND DELIVERY OF ANIONIC COMPOUNDS - The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided. | 2012-05-31 |
20120134927 | BETA CELL MARKER ANTIBODY - The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27. | 2012-05-31 |
20120134928 | MODULATION OF TERMINASE ACTIVITY AT TELOMERES AND DNA DOUBLE-STRAND BREAKS - The present invention is directed to compositions and methods concerning terminase proteins. In particular, the present invention is directed to terminase proteins and their function in processing telomeres and double-strand breaks. | 2012-05-31 |
20120134929 | TREATMENT OF MACROPHAGE-RELATED DISORDERS - The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound. | 2012-05-31 |
20120134930 | Pyrazine Derivatives for Bioconjugation - Provided are compounds and compositions of general Formula IX: E1-L-Ar-X-PA, that may be utilized in bioconjugation procedures, where Ar is a chromophore and PA is a functional group capable of being attached to any bioactive molecule of interest. The present invention provides Formulas I-III that are capable of being attached to a bioactive vector for the selective delivery of said photoactive pyrazine derivatives to a desired biological target. | 2012-05-31 |
20120134931 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE - Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier. | 2012-05-31 |
20120134932 | Manganese-Oxo Clusters as Contrast Agents for Magnetic Resonance Imaging - Nanoparticles for use as magnetic resonance imaging contrast agents are described. The nanoparticles are made up of a polymeric support and a manganese-oxo or manganses-iron-oxo cluster having magnetic properties suitable of a contrast agent. The manganese-oxo clusters may be Mn-12 clusters, which have known characteristics of a single molecule magnet. The polymer support may form a core particle which is coated by the clusters, or the clusters may be dispersed within the polymeric agent. | 2012-05-31 |
20120134933 | USE OF HIGH-DOSES OF MONOMERIC CONTRAST MEDIUM CONTAINING IODINE IN X-RAY DIAGNOSTICS, IN PARTICULAR IN INTERVENTIONAL X-RAY DIAGNOSTICS AND IN RADIATION THERAPY ASSISTED BY CONTRAST MEDIA CONTAINING IODINE - The invention relates to a diagnostic or therapeutic composition comprising a monomeric X-ray contrast medium containing iodine, in particular iopromide, for use in an X-ray assisted diagnosis or therapy and for the use of high doses of an X-ray contrast medium given to a patient, in particular patients with restricted kidney function. | 2012-05-31 |
20120134934 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF - Alkaloid aminoester derivatives according to formula (I) and (VI) act as muscarinic receptor antagonists. | 2012-05-31 |
20120134935 | USE OF MOMETASONE FUROATE FOR TREATING AIRWAY PASSAGE AND LUNG DISEASE - The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed. | 2012-05-31 |
20120134936 | Tooth Whitener - A tooth whitener is provided, including a water-in-oil (W/O) emulsion phase including: a discontinuous phase comprising a peroxide, a hydrophilic solvent, and a polyol, and a continuous phase comprising a glycerol monooleate, a polymer and a polyol, wherein the tooth whitener is flowable upon being applied to teeth and is solidified by the action of moisture after being applied to teeth, and then is adhered and fixed to teeth, and wherein the glycerol monooleate is in an amount of 15% to 95% by weight, based on total weight of the tooth whitener composition. | 2012-05-31 |
20120134937 | PERSONAL CARE COMPOSITIONS HAVING REDUCED EYE IRRITATION - The present invention is directed to a stable, minimal energy required self-assembling lamellar and spherulitic composition comprising: mixture water, fatty alcohol, fatty acid, salt of fatty acid, polyglyceryl fatty acid ester and oils. The present invention relates to composition that can benefit eye mildness, even distribution of sunscreen physical filters on skin and enhanced stability. | 2012-05-31 |
20120134938 | Melanin Promoting Topical Composition - The invention provides sunless tanning compositions for application to skin comprising an effective amount of at least one dopamine precursor, an effective amount of curcumin and a dermatologically acceptable carrier. Methods for preparation of said compositions are disclosed. When applied to the skin, the compositions may be used darken skin. | 2012-05-31 |
20120134939 | Water-In-Oil Emulsion Sunscreen Cosmetic Composition - To provide a low-viscosity water-in-oil emulsion sunscreen cosmetic composition which is extremely excellent in UV protective enhancing effect (as the protective boosting effect of the UV absorption capability thereof) over a broad UV radiation region and has superior feeling in use (smooth feeling, dry feeling, and non-sticky feeling, etc.). A water-in-oil emulsion sunscreen cosmetic composition comprising (a) from 0.01 to 10% by mass of a water-soluble polymer and (b) from 0.01 to 30% by mass of a UV absorbent, and having a viscosity of at most 10,000 mPa·s (as measured with a B-type viscometer at 30° C.), wherein the aqueous phase accounts for at most 45% by mass. | 2012-05-31 |
20120134940 | NANODISPERSIONS - The invention provides process for making water-soluble nano-dispersions of water-insoluble materials in a water-soluble carrier material comprising the steps of:
| 2012-05-31 |
20120134941 | METHOD FOR SMOOTHING OUT THE SKIN BY FILLING IN RECESSED PORTIONS - The invention relates to a method for smoothing out the skin by filling in recessed portions of the skin, said method comprising filling the recessed portions by means of a filling-in product which has an elastic modulus of greater than 20 000 Pascals at 25° C. for a stress frequency of 1 Hertz, a flow point of greater than 500 Pascals, and, for applied stresses of less than the yield stress, a viscosity of greater than 100000 Pa.s, the product being such that, once applied in said recessed portions of the skin, its mechanical properties change subsequent to a reaction other than an evaporation reaction or a laser polymerization re action. | 2012-05-31 |
20120134942 | Hybrid copolymer compositions for personal care applications - A personal care composition includes a hybrid copolymer including at least one ethylenically unsaturated monomer and a naturally derived hydroxyl containing chain transfer agent as an end group, a hybrid synthetic copolymer including one or more synthetic polymers derived from the at least one ethylenically unsaturated monomer with at least one initiator fragment as an end group and an effective amount of a cosmetic or personal care additive. | 2012-05-31 |
20120134943 | Topical Compositions Comprising An Alkoxylated Diphenylacrylate Compound And An Aryl Carboxylic Ester - A topical composition containing an alkoxylated diphenylacrylate compound and an aryl carboxylic ester is provided. Preferably, the topical composition is a sunscreen composition containing α-ethylhexyl α-cyano-β-(4-methoxyphenyl)-β-phenylacrylate and 2-phenylethyl benzoate, and optionally further containing 4,4′-t-butyl methoxydibenzoylmethane, which is characterized by improved photo-protection of the skin and is effective in preventing/reducing photo-damage of the skin upon exposure to sunlight or other sources of light in the ultraviolet (UV), visible, and infrared (IR) ranges. | 2012-05-31 |
20120134944 | Whitening Agent And Skin External Preparation - The present invention provides a compound having an excellent inhibitory action on melanin production and being useful as a whitening agent, and a skin external preparation containing the compound. The whitening agent of the present invention comprises, as an active ingredient, a heterocyclic compound represented by formula (1) or a pharmacologically acceptable salt thereof: | 2012-05-31 |
20120134945 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION - The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin. | 2012-05-31 |
20120134946 | COMPOSITION HAVING ANTIOXIDANT AND WHITENING EFFECTS CONTAINING A CONCENTRATE OF KOREAN RICE WINE - Disclosed is a composition containing a concentrate of Korean rice wine as an active ingredient. The composition exhibits antioxidant and whitening effects, and thus can be variously used in the fields of cosmetics, functional food or medicine. | 2012-05-31 |
20120134947 | ANTIPERSPIRANT COMPOSITIONS AND PRODUCTS HAVING COOLING SENSATION EFFECTS AND METHODS FOR MAKING THE SAME - A personal care product comprises an antiperspirant product that is housed within a container. The antiperspirant product includes a first portion comprising a dispersed cooling sensation agent. A second portion has a composition different from the first portion and comprises a solubilizer. | 2012-05-31 |
20120134948 | ANTIMICROBIAL ETHER GUANIDINES - The present invention relates to the use of at least one ether guanidine of the general formula (I) | 2012-05-31 |
20120134949 | POLYMERIC COLLAGEN BIOMATERIALS - This invention relates to the production of biomaterials from polymeric collagen (PC) and its seeding with cells and other components of biomaterials. Polymeric collagen is isolated from tissue, suspended in an acidic solution, and then neutralised at low temperature. The neutralised suspension is then seeded with biomaterial components, such as cells, and the polymeric collagen aggregated to form a biomaterial comprising the biomaterial components. Polymeric collagen biomaterials produced as described herein may therefore be useful in a range of tissue engineering applications. | 2012-05-31 |
20120134950 | Adhesion-Promoting thin Film and Moisture Resistant Skin Barrier Compositions - Adhesion-promoting, thin film, moisture resistant skin barrier formulations are composed of a fugitive solvent mixture consisting of t-butanol and an alkane fraction composed of at least one alkane, where the t-butanol is in the range of 40-70% by weight of the solvent mixture, and a film-forming solute dissolved in the fugitive solvent mixture. The formulations may also include one or more optional ingredients such as antimicrobial and/or bioactive agents. When applied to the skin, the formulations improve the adhesion of various classes of medical adhesives used to attach a variety of medical devices to the skin and create a thin, flexible and elastic continuous barrier film on the skin to protect against body fluids and incontinence. | 2012-05-31 |
20120134951 | Topical Gels and Methods of Using the Same - Provided according to some embodiments of the invention are topical gels that may release nitric oxide. Also provided are methods of using such topical gels in the treatment of wounds and other skin ailments. The topical gels comprise diazeniutndiolate-functionalized polysiloxane macromolecules. | 2012-05-31 |
20120134952 | Antiviral Method - This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof. | 2012-05-31 |
20120134953 | ANTI-MICROBIAL COMPOSITION - Anti-microbial compositions including an anti-microbial polymer containing silicon-containing quaternary ammonium groups, polyvinyl alcohol (PVA), at least one short chain alcohol, optional fragrance, and water are provided. The anti-microbial compositions may be used to disinfect both porous and non-porous surfaces. Exemplary compositions may include 0.1-10 wt % of the anti-microbial polymer containing silicon-containing quaternary ammonium groups, 0.1-10 wt % polyvinyl alcohol (PVA), 1.0-20 wt % isopropyl alcohol, optional fragrance, and water. | 2012-05-31 |
20120134954 | DEFENSIN-ANTIGEN FUSION PROTEINS - The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection. | 2012-05-31 |
20120134955 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE - The invention is to provide a novel anticancer agent or sensitizer for cancer chemotherapy or radiotherapy. A compound of a general formula (I): wherein A means an aryl group or a heteroaryl group, or a group of a formula (a):; R | 2012-05-31 |
20120134956 | Colloidal metal compositions and methods - The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer. | 2012-05-31 |
20120134957 | LATENT PHASE VIRAL INTERLEUKIN-10-(VII-10) AND USES THEREOF - The present invention relates to a purified nucleic acid sequence encoding a homologue of human interleukin 10 (IL-10), wherein said IL-10 homologue is expressed during the latent phase of infection by a virus of the herpesvirideae group. The present invention also relates to uses of this polypeptide, in particular for diagnosing disease states and screening for modulator and inhibitor compounds of such polypeptides and in turn the virus itself, screening for infection in vertebrates and biological tissue, cleansing of infected biological tissues, and in the treatment and/or prophylaxis and/or diagnosis of disease caused by a virus of the herpesvirideae group. | 2012-05-31 |
20120134958 | HYDROXYETHYL STARCH-CONTAINING POLYPEPTIDE COMPOSITIONS - The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures. | 2012-05-31 |
20120134959 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES - The invention relates to pyrimidine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds. | 2012-05-31 |
20120134960 | GLYCOSYLATED HUMAN ALPHA INTERFERON MUTEINS, METHOD FOR OBTAINING THEM AND USE - A recombinant human interferon-alpha mutein that contains at least one glycosylation site at a position of its amino acid sequence that is a part of an alpha helix-type secondary structure, a gene encoding the mutein, a method for producing the gene, a method for obtaining an eukaryotic cell producing the mutein, a method for producing the mutein, a process for purifying the mutein, a pharmaceutical composition containing the mutein, and the use of the mutein for manufacturing a medicament. | 2012-05-31 |
20120134961 | Interferon-alpha (IFN-alpha) Fused Protein Having IFN-alpha and Cytoplasmic Transduction Peptide (CTP) - Disclosed is an interferon-α (IFN-α) fused protein having IFN-α fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-α, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses. | 2012-05-31 |
20120134962 | METHODS AND COMPOSITIONS FOR TISSUE REGENERATION - Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, IL-6, IL-8, TGFα, and TNFα, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof. | 2012-05-31 |
20120134963 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY - Provided are viral sensitizing compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided. | 2012-05-31 |
20120134964 | HUMAN MATRIX METALLOPROTEINASE-8 GENE DELIVERY ENHANCES THE ONCOLYTIC ACTIVITY OF A REPLICATING ADENOVIRUS - The present invention discloses a method of treating cancer in a subject. This involves co-administering a replicating virus and a matrix metalloproteinase to the subject under conditions effective to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses. This involves co-administering a replicating virus and a matrix metalloproteinase to the tumor mass under conditions effective to enhance the delivery to and distribution within the tumor mass of therapeutic viruses. Another aspect relates to a cancer therapeutic. This involves a replicating virus and a matrix metalloproteinase. | 2012-05-31 |
20120134965 | METHOD FOR DIFFERENTIATION OF STEM CELLS INTO VASCULAR CELLS AND THE INDUCTION OF ANGIOGENESIS USING THE SAME - The present invention relates to a method for differentiating stem cells into vascular cells by culturing them in the form of a three-dimensional cell cluster and the use of the three-dimensional cell cluster for angiogenesis. Specifically, the present invention teaches a method for differentiating stem cells into vascular cells comprising culturing stem cells by adhering them onto a culture plate with a surface having a hydrophobic property or a culture plate onto which a growth factor is immobilized, wherein the cultured stem cells are later detached from the culture plate as their density increases to form a three-dimensional cell cluster and grown in the form of a three-dimensional cell cluster while differentiating into vascular cells. Also disclosed is the use of a three-dimensional cell cluster composed of the vascular cells differentiated from stem cells by the above method as a cell therapy agent for angiogenesis. | 2012-05-31 |
20120134966 | EMBRYONIC STEM CELL SPECIFIC MICRORNAS PROMOTE INDUCED PLURIPOTENCY - The methods of the present application describe that introduction of physiologically relevant miRNAs can enhance or modulate somatic cell reprogramming, generating induced pluripotent stem cells (iPS cells). These miRNAs did not further enhance reprogramming in the presence of cMyc. Furthermore, unlike previously described methods of generating iPS cells, such as through the introduction of genetic elements using viruses, the methods of the present invention reduce the risk of activating oncogenes in the iPS cells. The methods of the invention generate iPS cells that can be free of genetic modifications and thus have greater potential for use as therapeutic agents than those generated by existing methods. | 2012-05-31 |
20120134967 | Scaffolds For Cell Transplantation - A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material. | 2012-05-31 |
20120134968 | Composition for manufacturing a scaffold for tissue engineering, and a method of making it - The invention relates to a composition comprising a mixture of at least one degradable hydrogel and at least one kind of degradable and surface cross-linked particle. The at least one kind of degradable and surface cross-linked particle comprises a material which degrades faster than the degradable hydrogel. The composition can further comprise one or more species of living cells. The invention relates also to a method of manufacturing the composition, as well as to a method of manufacturing a scaffold for tissue engineering using the composition. | 2012-05-31 |
20120134969 | PHARMACEUTICAL COMPOSITION CONTAINING NUCLEAR FACTOR INVOLVED IN PROLIFERATION AND DIFFERENTIATION OF CENTRAL NEURONAL CELLS - With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided. | 2012-05-31 |
20120134970 | Viral Vectors Encoding Multiple Highly Homologus Non-Viral Polypeptides And The Use Of Same - The present invention relates to compositions and methods for creation of vector nucleic acid sequences (e.g., retroviral nucleic acid sequences) that comprise two or more exogenous nucleic acid sequences that encode highly homologous (e.g., identical) polypeptide sequences, yet wherein at least one of the exogenous nucleic acid sequences has been mutated using degenerate codons for purpose of reducing homology between the two or more exogenous nucleic acid sequences while maintaining the encoded polypeptide sequence. Preferred nucleic acid sequences include those encoding multi-chimeric immune receptor (CIR) genes. Specific nucleic acid sequences of such CIR genes are also disclosed. | 2012-05-31 |
20120134971 | ENGINEERED BIOLOGICAL PACEMAKERS - Biological pacemakers engineered to intrinsically generate rhythmic excitations are disclosed. In addition, methods of producing the biological pacemakers are disclosed. Methods of treating or preventing arrhythmia and heart disease associated with a defective pacemakers are also disclosed. | 2012-05-31 |
20120134972 | Novel Polypeptides Having Endolysin Activity And Uses Thereof - The present invention provides isolated polypeptides comprising a fragment of the amino acid sequence of SEQ ID NO:1, or a variant, derivative or fusion thereof, which is capable of binding specifically to and lysing cells of | 2012-05-31 |
20120134973 | NOVEL USE OF PROBIOTICS - The present invention relates to use of a probiotic to normalize abnormal inflammation markers. The present invention also relates to use of a probiotic for preventing and/or treating low-grade inflammation. Further, the present invention relates to use of a probiotic for preventing and/or treating disorders and/or diseases relating to low-grade inflammation. | 2012-05-31 |
20120134974 | METHODS FOR REMOVING PLASMA - A method for preparing a blood component composition for reducing risk of transfusion related injury includes passing a blood component composition through a tangential flow filter unit comprising one or more filter membranes. A diafiltration solution is added to the blood component composition during the filtration process. Non-cellular plasma components, including antibodies, are removed from the blood component composition by the tangential flow filtration. | 2012-05-31 |
20120134975 | Biological targeting compositions and methods of using the same - Modified red blood cells are described. In an embodiment, the modified red blood cell includes a target-binding agent. Targeted delivery of imaging agents, drugs, and peptide and protein pharmaceuticals using modified red blood cells are described. Processes for preparing the modified red blood cells, pharmaceutical and diagnostic compositions containing the same and methods of diagnosis and treatment involving the modified red blood cells are described. | 2012-05-31 |
20120134976 | ORAL FORMULATIONS FOR COUNTERACTING EFFECTS OF AGING - An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and | 2012-05-31 |
20120134977 | PRODRUGS CONTAINING ALBUMIN BINDING PROBE - The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof. | 2012-05-31 |
20120134978 | Cross-Linking of Superoxide Dismutase Monomers - A stabilized superoxide dismutase (SOD1) analogue, wherein the side chains of two amino acids on two different SOD1 monomers are connected is provided. A method of producing a stabilized superoxide disumutase (SOD1) analogue comprises reacting a first SOD1 monomer, a second SOD1 monomer, and a cross-linker. | 2012-05-31 |
20120134979 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SICKLE CELL DISEASE - Presented are mechanism based compositions and methods for treatment of SCD and SCD associated symptoms and disorders, particularly increased RBC sickling, HbS polymerization, hemolysis, tissue congestion and disruption and organ damage or failure in a mammal. The disclosed methods feature the identification of the heretofore unknown role of adenosine levels and signaling in the development of SCD and SCD associated symptoms and disorders. This discovery has lead to the identification of compositions for use as therapies for SCD and SCD associated disorders and symptoms in a mammal. | 2012-05-31 |
20120134980 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 2012-05-31 |
20120134981 | GENES LINKING SEVERAL COMPLICATIONS OF TYPE-2 DIABETES (T2D) - The invention provides means and methods to predict, in subjects affected by type II diabetes (T2D), the probability of developing complications which include, but are not limited to, micro/macrovascular disorder, hypertension, neuropathy, atrial fibrillation, nephropathy and other major adverse cardiovascular events (MACE) that are associated with the disease, by detecting one or more genetic features. The genetic features that are useful in prediction include, but are not limited to, genes, single nucleotide polymorphisms (SNPs) and other genomic markers. The invention further involves characterizing individuals based on the probability of developing complications related to T2D, such as, micro/macrovascular disorder, hypertension, neuropathy, atrial fibrillation, nephropathy or MACE, based on the identification of one or more aforementioned genetic features. Also described are combinations and kits for carrying out the above-described methods. | 2012-05-31 |
20120134982 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS - The present invention relates to polypeptides e.g. protease resistant polypeptides, immunoglobulin (antibody) single variable domains e.g. which are protease resistant and also to vascular endothelial growth factor (VEGF) antagonists comprising these. The invention further relates to uses, formulations, and compositions comprising such polypeptides e.g. for delivery to the eye. | 2012-05-31 |
20120134983 | Method for Identifying Interventions that Control the Translational Activity of Ribosomal Proteins in Different MRNA Expression - The present invention relates to systems and methods for screening compounds and/or mutant ribosomal proteins in a eukaryotic cell that increase or decrease the translation of a target gene and thereby ameliorate or revert a defective and/or undesired translation of a target gene. Disclosed are compounds and proteins as identified with the methods and systems of the invention, pharmaceutical and cosmetic compositions thereof, their uses for the preparation of a medicament, methods of treatment of a disease or condition or cosmetic condition related to the defective translation of a gene, for example genetic diseases such as Epidermolysis bullosa, as well as diagnostic measures practical for the clinical evaluation of such diseases or conditions. Also, kits are provided which comprise the identified compounds and/or proteins in addition to suitable means for performing the methods of the invention | 2012-05-31 |
20120134984 | MOLECULES WITH EXTENDED HALF-LIVES AND USES THEREOF - The invention is directed to a molecule comprising an albumin binding domain (ABD) and an FcRn binding moiety, wherein said molecule has enhanced pharmacologic properties in vivo. | 2012-05-31 |
20120134985 | METHODS FOR MODULATING METABOLIC AND CIRCADIAN RHYTHMS - The role of AMPK in arcadian rhythms and methods of screening for agents that modulate such rhythms are disclosed. Compositions that are useful for modulating such rhythms and uses thereof are also disclosed. | 2012-05-31 |
20120134986 | Methods of Prognosis for Non-Hodgkin Lymphoma - Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis. | 2012-05-31 |
20120134987 | KINASE INHIBITORS AND METHODS OF THEIR USE - New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer. | 2012-05-31 |
20120134988 | POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS - The invention provides methods of altering properties of Fc-containing molecule, comprising altering the sialylation of the oligosaccharides in the Fc region. Proteins having Fc regions having altered sialylation patterns are also provided. | 2012-05-31 |
20120134989 | ANTIBODY FORMULATIONS - Formulations of VLA-4 binding antibody are described. | 2012-05-31 |
20120134990 | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES - The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody. | 2012-05-31 |
20120134991 | COMPOSITIONS AND METHODS FOR MODULATING D1-D2 DOPAMINE RECEPTOR INTERACTION AND FUNCTION - The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling. | 2012-05-31 |
20120134992 | MESOTHELIN ANTIBODY PROTEIN FUSIONS AND METHODS OF USE - The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising a stress protein fused with an antibody binding protein in combination with an engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising an engineered antibody or fragment that binds specifically to mesothelin fused in frame with a biotin binding protein. The invention also provides fusion proteins comprising an engineered antibody or fragment, that binds to mesothelin, fused with an antibody binding protein. The invention also relates to methods of using fusion proteins of the invention to induce an immune response to mesothelin and to treat disease. | 2012-05-31 |
20120134993 | COMPOSITIONS AND METHODS FOR USING MULTISPECIFIC-BINDING PROTEINS COMPRISING AN ANTIBODY-RECEPTOR COMBINATION - Disclosed are bispecific binding proteins comprising a antibody/soluble receptor bispecific binding protein that reduces the biological activity of both VEGF-A and FGF. The FGF binding moieties are generally soluble FGFR3 or FGFR2. An Fc polypeptide is fused to the C-terminus of the FGF binding moiety and VEGF-A binding moiety are polypeptides fused using peptide or polypeptide linker sequences, and can be expressed as single bispecific binding protein. The bispecific antibody/soluble receptor binding proteins can be used to treat cancers characterized by solid tumor growth as well as other diseases. | 2012-05-31 |
20120134994 | MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 - The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. | 2012-05-31 |
20120134995 | METHOD FOR PREDICTING THE THERAPEUTIC RESPONSEIVENESS OF A PATIENT TO A MEDICAL TREATMENT WITH AN EGFR INHIBITOR - The invention provides a method of predicting the response of a patient affected with cancer to a treatment with an EGFR inhibitor, wherein the said method comprises detecting the level of expression of the phosphoprotein pP70S6k in sample from said subject. The invention also provides methods of treatment of cancer and or predicting the outcome of cancer. | 2012-05-31 |
20120134996 | Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products - Use of a monoclonal antibody directed against the extracellular domain of hepatocyte growth factor is disclosed for the preparation of a medicament for the treatment of tumors and/or metastases and of a diagnostic tool for detecting neoplastic cells as well as vectors comprising at least a portion of the nucleotide sequence encoding the anti-Met monoclonal antibody, products containing the anti-Met monoclonal antibody and/or at least one fragment thereof and at least one kinase inhibitor. | 2012-05-31 |
20120134997 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development. | 2012-05-31 |
20120134998 | SECRETED AP2 AND METHODS OF INHIBITING SAME - A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum. | 2012-05-31 |
20120134999 | PORIN B (PorB) AS A THERAPEUTIC TARGET FOR PREVENTION AND TREATMENT OF INFECTION BY CHLAMYDIA - The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit | 2012-05-31 |
20120135000 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS - The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. | 2012-05-31 |
20120135001 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DASATINIB FOR THE TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 2012-05-31 |
20120135002 | Compounds and Methods for the Treatment of Cancer - The present invention relates to a pharmaceutical composition comprising: a) at least one iron uptake inhibitor, and b) at least one vitamin D and/or at least one analog thereof and/or at least one vitamin D receptor modulator, and optionally a pharmaceutically acceptable carrier. | 2012-05-31 |
20120135003 | ANTI-ILT7 ANTIBODY - An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFNα. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFNα. | 2012-05-31 |
20120135004 | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 - The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). | 2012-05-31 |
20120135005 | ANTI-TNF-a ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-α. | 2012-05-31 |
20120135006 | ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES - Ultra high affinity antibodies with binding affinities in the range of 10 | 2012-05-31 |
20120135007 | Anti-LPS Enriched Immunoglobulin Preparations For The Treatment And/Or Prophylaxis Of A Pathologic Disorder - The invention relates to the use of preparations enriched with anti LPS antibodies, such as those derived from mammalian colostrum or avian eggs, and optionally further antibodies against disease-associated antigens, colostrums, milk or milk product component/s and any adjuvants for treating, delaying or preventing the progression of a pathologic disorder such as chronic liver disease, cirrhosis and any complication or disorder associated therewith. The invention further relates to combined compositions comprising a combination of anti-LPS enriched antibody preparations and antibodies recognizing at least one antigen specific for a pathologic disorder and uses thereof in the treatment of immune-related disorders. | 2012-05-31 |
20120135008 | METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN - Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided. | 2012-05-31 |
20120135009 | Cleaved and Phosphorylated CRMP2 as Blood Marker of Inflammatory Diseases of the Central Nervous System - The present invention relates to a method for in vitro prognosis, diagnosis and/or monitoring of an inflammatory disease of the central nervous system in a subject, said method comprising detecting, in a sample of cells of the immune system from the subject, the presence of a Collapsin Response Mediator Protein 2 (CRMP2) which is phosphorylated on tyrosine 479 (Y479), and optionally further phosphorylated on serine 465 (S465), wherein the detection of the presence of Y479-phosphorylated CRMP2, which is optionally further phosphorylated on serine 465, is indicative of an inflammatory disease of the central nervous system. | 2012-05-31 |
20120135010 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR - An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with an affinity constant (K | 2012-05-31 |
20120135011 | Method for in vivo expansion of T regulatory cells - Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune response by regulating T regulatory cells. | 2012-05-31 |
20120135012 | TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS - Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases. | 2012-05-31 |
20120135013 | CD45 and Methods and Compounds Related Thereto - Disclosed herein are compounds, compositions and methods for preventing, reducing or inhibiting an amount of protein tyrosine phosphatase receptor type C (CD45) expressed or activity of CD45 in a cell or a subject. Also disclosed are methods for preventing, inhibiting or treating an infection in a cell or a subject immunizing a subject or enhancing a subject's immune response against an infection preventing, reducing or inhibiting the susceptibility of a cell or a subject to an infection or subsequent pathogenesis and morbidity due to the infection and preventing, reducing, and inhibiting apoptosis caused by or resulting from a biological agent in a cell or a subject which comprises preventing, reducing or inhibiting an amount of protein tyrosine phosphatase receptor type C (CD45) expressed or activity of CD45 in the cell or the subject. | 2012-05-31 |
20120135014 | SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) AND ASSOCIATION WITH RESISTANCE TO IMMUNE TOLERANCE INDUCTION - This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy. | 2012-05-31 |
20120135015 | Induction of Pancreatic Stem Cells by Transient Overexpression of Reprogramming Factors and PDX1 Selection - Methods for generating pancreatic stem cells from a pancreatic tissue of 24-week old mice by transient overexpression of reprogramming factors combined with Pdx1 selection is described herein. The generated cells were designated as iPaS (induced pancreatic stem) cells and exhibit the same morphology as the pancreatic stem cells previously established from young donors without genetic manipulation and express genetic markers of endoderm and pancreatic progenitors. Transplantation of the iPaS cells into nude mice resulted in no teratoma formation. Moreover, iPaS cells were able to differentiate into insulin-producing cells more efficiently than ES cells. In addition, the technology of transient overexpression of reprogramming factors and tissue-specific selection of the present invention may also be useful for the generation of other tissue-specific stem cells. | 2012-05-31 |
20120135016 | INDUCTION OF NEUROGENESIS AND STEM CELL THERAPY IN COMBINATION WITH COPOLYMER 1 - A method for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells comprises administering to an individual in need thereof an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide, a Copolymer 1-related peptide, and activated T cells which have been activated by Copolymer 1, a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide. The method is particularly useful for stem cell therapy in combination with the agent. | 2012-05-31 |
20120135017 | STABLE DRY POWDER COMPOSITION COMPRISING BIOLOGICALLY ACTIVE MICROORGANISMS AND/OR BIOACTIVE MATERIALS AND METHODS OF MAKING - The present invention relates to embedding live or dead microorganisms and/or bioactive materials in a protective dry formulation matrix, wherein the formulation includes the bioactive microorganism or material, a formulation stabilizer agent, and a protective agent. The formulation is prepared by dispersing all the solid components in a solution, with or without a vacuum, and cooling the solution to a temperature above its freezing temperature. The methods include a primary drying step of the formulation at a desired temperature and time period, and an accelerated secondary drying step under maximum vacuum and elevated temperature, to achieve a final desirable water activity of the dry material. | 2012-05-31 |